Kaia Health Appoints Lumeris Co-Founder Nigel Ohrenstein as President to Accelerate Growth, Increase Access to Affordable High-Quality Care

Kaia Health, the digital therapeutics company on a mission to democratize access to healthcare, today announced the appointment of Nigel Ohrenstein—healthcare entrepreneur and Lumeris co-founder—as president to accelerate the growth and further advance Kaia Health’s strategy as the market leader in musculoskeletal (MSK) care.

Kaia Health covers 60 million lives globally and has transformed MSK care by delivering clinically proven care using computer vision technology through the camera of a smartphone, anytime, anywhere.

Ohrenstein brings over 20 years of experience dedicated to transforming the healthcare system by delivering solutions that reduce the cost of care, improve the quality of care, and enhance the patient experience. As co-founder of Lumeris, Ohrenstein helped build Lumeris into the leading value-based care company.

“Nigel’s combination of business intelligence and dedication to improving both the quality and cost of care will accelerate Kaia Health’s next phase of growth, further our lead in the MSK market, and advance our mission to make effective therapies accessible to patients anywhere and at any time,” said Konstantin Mehl, Kaia Health Founder and CEO.

Kaia Health’s solution solves one of the primary issues in healthcare, namely access to care. Kaia Health recently extended access further to those who need in-home physical therapy by partnering with Luna On-Demand Physical Therapy.

Kaia Health is the most clinically validated digital MSK solution in the market and partners with leading U.S. employers and providers, including MetLife, Harvard Pilgrim Health Care, and VirginPulse. In a recent clinical study, its market-leading computer vision technology was shown to be as accurate as physical therapists and in many ways is more powerful, as it delivers the same quality of care to every patient, every time, solving another major issue in healthcare around health equity.

“Kaia Health is an exceptional, mission-driven company that is transforming healthcare by furthering access to affordable high-quality care,” Ohrenstein said. “I am delighted to join an incredible team that is solving four of healthcare’s largest challenges: access, quality, affordability, and health equity.”

Earlier this year, Kaia Health sealed a $75 million Series C round to expand clinical capabilities, heavily invest in computer vision technology, and transform digital therapies in the U.S. and Europe.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.